Our results suggest that higher densities of CD20+ B cells in the tumor center tend to be associated with longer cancer-specific survival (p = 0.065), but no statistically significant survival associations were found for either B cell or plasma cell densities. The gene discussed is MS4A1; the disease is cancer.